Coya reports positive proof-of-concept data for COYA 302 in ALS; Treg function up, biomarkers down, ALSFRS stable

Coya Therapeutics, Inc.

Treatment with IL-2/CTLA4-Ig (COYA 302) over 48 weeks significantly increased Treg suppressive function and Treg numbers in 4 ALS patients.
Biomarkers of oxidative stress (4-HNE, ox-LDL) were reduced; mean ALSFRS-R scores not statistically different from baseline, suggesting disease stabilization.
Adverse events limited to mild injection site reactions; no deaths or serious AEs; all 4 patients completed the study.
Study is open-label, single-arm, proof-of-concept; data supports further development of COYA 302 for ALS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.